Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer

Overview

In extrahepatic bile duct cancer and pancreatic cancer, we will treat postoperatively with COX2 inhibitor and assess survival rate and recurrent rate.

Patients : total 220 patients * Extrahepatic bile duct cancer : 55 patients for administration of COX2 55 patients for control group * Pancreas cancer : 55 patients for administration of COX2 55 patients for control group Indication * After operation of extrahepatic bile duct cancer or pancreas cancer * Age : 19 - 70 years old * The patients who agree to consent sheet. Contraindication * Impossible of administration due to severe postoperative morbidities (bleeding, bowel obstruction, pancreatic fistula, biliary fistula) * Preexisting heart disease: Ischemic heart disease, Heart failure. Severe uncontrolled hypertension (systolic BP\>160) * Renal insufficiency: CCR \< 50 or serum creatinin \>3.0 * Hepatic insufficiency: Liver cirrhosis or active hepatitis * Preexisting allergic reaction history for NSAIDs or Sulfonamide * Current drug intake: Warfarin. Lithium, Fluconazole, Aspirin, Celecoxib * Preexisting Asthma. Especially aspirin-sensitive asthma. * Contraindications to aspirin, clopidogrel or celecoxib * The patients who refuse trial * The patients who has Psychogenic problem Allocation * We will allocate patients randomly, to administration group or control group Methods * From postoperative third day, administration will be started * celecoxib 200mg bid for 6 months for administration group * Follow up and assess recurrence rate and survival rate

Conditions

Interventions

Eligibility

Locations (1)

Outcomes